MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krejcí, A.
Right arrow Articles by Tucek, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krejcí, A.
Right arrow Articles by Tucek, S.

Vol. 61, Issue 6, 1267-1272, June 2002

ACCELERATED COMMUNICATION
Quantitation of mRNAs for M1 to M5 Subtypes of Muscarinic Receptors in Rat Heart and Brain Cortex

Alena Krejcí and Stanislav Tucek

Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

It has been generally accepted that, of the five subtypes of muscarinic receptors (M1-M5), only the M2 subtype is expressed in mammalian heart. This notion has recently been challenged by a series of reports indicating that mRNAs for some or all non-M2 subtypes are also present in mammalian heart, in parallel with the M2 mRNA. However, the quantities of relevant mRNAs reported to be present in the heart are not known, which makes it difficult to evaluate their likely significance. We measured the concentrations of the five muscarinic mRNAs by competitive reverse transcription-polymerase chain reaction and discovered that the M2 mRNA represents more than 90% of total muscarinic mRNAs in rat atria and in either ventricle. The concentrations of total muscarinic mRNAs and of the M2 mRNA were more than twice as high in the atria than in the ventricles. mRNAs for all non-M2 muscarinic receptor subtypes were also detected but represented less than 1% (M1 and M4), less than 3% (M3), and less than 5% (M5) of total muscarinic RNAs in the atria and ventricles. The findings support the concept of the prevalent role of the M2 muscarinic receptors in the cholinergic control of the heart. When the same method of quantitation was applied to rat cerebral cortex, mRNAs for individual subtypes were found to represent 36% (M1), 21% (M2), 25% (M3), 11% (M4), and 7% (M5) of total muscarinic mRNAs.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Toxicol SciHome page
P. A. Dabisch, F. To, E. K. Kerut, M. S. Horsmon, and R. J. Mioduszewski
Multiple Exposures to Sarin Vapor Result in Parasympathetic Dysfunction in the Eye but not the Heart
Toxicol. Sci., September 1, 2007; 99(1): 354 - 361.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
W. J. Zang, L. N. Chen, X. J. Yu, P. Fang, J. Lu, and Q. Sun
Comparison of effects of acetylcholine on electromechanical characteristics in guinea-pig atrium and ventricle
Exp Physiol, January 1, 2005; 90(1): 123 - 130.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics